Nasdaq · Healthcare

Neuronetics, Inc. (STIM)

As-reported financials and recent SEC filings for Neuronetics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$149.2M

Net income

$-39.0M

Net margin

-26.1%

Diluted EPS

$-0.59

ROE

-148.6%

P/E (TTM)

—

Market cap

—

Debt / equity

2.5×

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$149.2M	$74.9M	$71.3M	$65.2M	$55.3M
Gross profit	$72.3M	$54.2M	$51.7M	$49.7M	$43.7M
Operating income	$-31.4M	$-34.6M	$-30.6M	$-35.1M	$-27.6M
Net income	$-39.0M	$-43.7M	$-30.2M	$-37.2M	$-31.2M
Diluted EPS	$-0.59	$-0.69	$-0.53	$-0.69	$-0.61

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

8-K2026-06-23

42026-06-17

42026-06-17

1442026-06-08

42026-05-29

42026-05-29

42026-05-29

42026-05-29

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on STIM

Search Neuronetics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.